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INTRODUCTION 
            Malaria, one of the commonest parasitic diseases of the world, is 
prevalent throughout the tropics and subtropics1. It is the most important 
devastating 2 parasitic disease of humans, affecting more than 1 billion people 
and causing about 1 to 3 million deaths worldwide each year. 
HISTORY 
        Malaria (or ague 3—as it was called earlier) has been known from 
antiquity. Seasonal intermittent fevers with chills and shivering, recorded in 
religious and medical texts of ancient Indian, Chinese and Assyrian 
civilizations, are believed to be due to malaria. Charaka and Susrutha have 
described the disease and have mentioned its association with mosquitoes. 
        Hippocrates as early in 5th century BC gave a detailed account of the 
disease. The relationship between the disease and stagnant water, swamps and 
marshy land was recognized and measures to control the disease by effective 
drainage were practiced in Rome and Greece in the 6th century AD. 
        The name ‘malaria’ (mal-bad, aria-air) was given in the 18th century in 
Italy. Malaria was then believed to be due to mal-air or bad air. “Paludism”- is 
another name for malaria. “Palus” in Latin means marsh. The recent 
demonstration of a specific parasitic antigen in Egyptian mummies probably 
indicates that malaria was present thousands of years ago. 
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        Alphone Laveran, a French army surgeon in Algeria, discovered the 
causative organism of malaria in a patient in 1880. In  1886, Golgi in Italy 
described the asexual development of the parasite in RBCs, which came to be 
called the Golgi cycle.  
         Romanowsky, from Russia in 1891, developed a method of staining 
malarial parasite present in blood films. Three different malarial parasites 
infecting man namely P.vivax, P. malariae, P.falciparum were described in 
Italy between 1886 and 1890. The 4th species P. ovale was identified only in 
1922. The mode of transmission of the disease was established in 1897, when 
RONALD ROSS, in Secunderabad, India identified the developing stages of 
malarial parasites in mosquitoes. This led to various measures for the control 
and possible eradication of malaria by mosquito control. Both Ross (1902) and 
Laveran (1907) won the Nobel Prize for their discoveries. 
EPIDEMIOLOGY 
GLOBAL  
Malaria due to P.falciparum and P. ovale is primarily a disease of 
tropics, whereas malaria due to P. malaria occurs extensively in the subtropics 
and temperate zones. Vivax malaria is more commonly seen both in tropics and 
subtropics than all other types of malaria 4. 
         The incidence of malaria worldwide is estimated to be 300-500 million 
clinical cases every year, of which 90% occurs in sub Saharan Africa. Malaria 
is reported to cause 1.1 to 2.7 million deaths worldwide each year, of which 
about 1 million are children under the age of 5 years. 
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 Malaria has been eliminated from North America, Europe and Russia. 
But P. vivax infection is common in Central America. The prevalence of P. 
vivax and P. falciparum is equal in South America. The incidence of malaria in 
USA in the year 1999 was 1666. In UK it was 1600 – 2500 and the deaths due 
to malaria was 9 –15. In Australia the incidence was 54. 
       The incidence is on the increase in both the Urban and periurban areas of 
South Asia. Military conflicts and civil unrest, along with unfavorable 
ecological changes, have greatly contributed to malaria epidemics, as large 
number of unprotected, non- immune and physically weakened refugees move 
into malaria endemic areas. Such population movements contribute to new 
malaria outbreaks and make epidemic prone areas more explosive. 
           All member countries of SEAR (except Maldives) have endemic areas 
in where, about 90% of the native population reside. There were over 23.7 
million estimated cases of malaria in the region during 1998. In spite of the 
increasing frequency of drug resistant P.falciparum, the estimated numbers of 
deaths decreased because of the introduction of the new anti malarial drugs. 
INDIA  
In India, with the implementation of Modified Plan of Operation (MPO) 
in 1977, the upsurge of malaria dropped down from 6.74 million cases in 1976 
to 2.1 million cases 5 in 1984. During the year 2001, there were 0.98 million 
reported cases of malaria in the country out of which 0.46 million were 
P.falciparum cases. 431 deaths were reported during the same period. A decline 
of 3.42% in total malaria cases and 11.09% in P.falciparum incidence were 
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recorded in the country as compared to the corresponding period in the year 
2000. 
            Northeastern states contribute 8.5 to 11% of total malaria cases and 13 
to 15% of total malaria mortality in the country. Among the northeastern states, 
Assam reports maximum followed by Arunachal Pradesh, Tripura, and 
Meghalaya. During 2001, maximum deaths were reported from Assam 
followed by Mizoram and Tripura. 
 Hence in order to bring down the incidence and morbidity in the 
country, the national malaria eradication followed by the control programmes 
were implemented. 
MALARIA PROGRAMMES  
I. National anti – malaria programme 
            National malaria control programme (NMCP) was launched in India in 
April 1953. In this programme, indoor spraying of DDT was carried out 
(1g/sqm of surface area) twice a year in endemic areas where spleen rate was 
10%. The results of the programme was highly successful in that the incidence 
of malaria declined from 75 million cases in 1953 to 2 million cases in 1958. 
Encouraged by this result the Ministry of health changed the strategy from 
control to eradication, and launched National malaria eradication programme 
(NMEP) in 1958. 
            Considering the resurgence of malaria, a Modified plan of operation 
(MPO) to control malaria was launched and put in to operation from April 
1977. It has the following objectives: 
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1. To prevent deaths and reduce morbidity due to malaria 
2. To maintain agricultural and industrial production by undertaking 
intensive antimalarial measures in such areas to consolidate the gains so 
far achieved. 
Flexibility in the policies according to the epidemiological situation and 
local conditions is an essential feature in this programme. 
II. Malaria control through primary health care 
          This new approach to control malaria was approved by WHO in 1978.  In 1994, 
due to resurgence of malaria the Government of India evolved Malaria action 
programme (MAP) and guidelines were distributed to all the states for prediction, 
early detection and effective management to malaria outbreaks at district level. 
  The antimalarial activities have been intensified with additional inputs in 
100 selected districts of the states including Tamilnadu with ‘Enhanced malaria 
control project’ with the support of World Bank in September 1997. 
 In 1999, the Government of India decided to drop the term “National 
malaria eradication programme” and renamed it as “National anti-malaria 
programme”. 
 In spite these control measures and effective antimalarial treatment there 
is still significant incidence and prevalence of malaria, which is mainly due to 
treatment failure and vector resistance. One of the main causes for treatment 
failure is the development of resistance by the malarial parasites to many of the 
antimalarial drugs especially to chloroquine. 
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NEWER DRUGS IN MALARIA 
 Hence management of drug resistance is an urgent need to decrease the 
incidence of malaria. Several commonly used drugs such as verapamil 6-16 
chlorpheniramine maleate 7, tricyclic antidepressants 7, desipramine 7,9,14,17, 
cyproheptadine 7, chlorpromazine 14 have been shown to reverse the resistance 
of P.falciparum to chloroquine in vitro.  Mostly the antihypertensive, 
Verapamil is proved as an effective chemosensitizer. Thus although the first 
line antimalarial drug chloroquine appears to lose its importance in most part of 
the world, this inexpensive, rapid acting well tolerated antimalarial may be still 
used with the same efficacy by combining it with effective resistance reversers. 
 Therefore if chloroquine is combined with anyone of the above 
resistance reversing drugs, the efficacy of chloroquine is expected to be 
retained, in resistant malaria. Verapamil is reported to reverse chloroquine 
resistance by several in vitro studies. Whether verapamil will have such action 
when used clinically? Will verapamil facilitate the action of chloroquine in 
sensitive malaria and bring out a synergistic effect?  
 Thus, in order to find out the effect of verapamil in malaria irrespective 
of the sensitivity status, the present study was under taken. 
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AIM OF THE STUDY 
 
 
 
The aim of the study was to find out  
 
1. The effect of Verapamil in malaria 
2. Whether it has any facilitatory action when given along with  
Chloroquine and          
    3.   Whether it is safe. 
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REVIEW OF LITERATURE 
Malaria occurs in all the countries extending 40 degree South to 60 
degree North. The tropical zone is the endemic home of all malarial parasites. 
All the malarial parasites belong to the genus Plasmodium, and there are 4 
different species that transmit malaria to humans. 
TYPES OF MALARIAL PARASITES 
  1.  P. malariae (Laveran- 1881) & (Grassi & Feletti-1890) 
                            This is the parasite of quartan malaria. Laveran first  
                             studied this species and gave the name, which is  
      still retained.                         
  2.  P. vivax (Grassi & Feletti-1890)  
This is the parasite of benign tertian or vivax malaria. The 
specific name “vivax” is derived from the Latin word ‘vivere’ 
which means - to live and indicates the movement. 
3.  P. falciparum (Welch- 1897)  
This is the parasite of malignant tertian or falciparum 
malaria. The specific name “falciparum” from Latin (falx- a 
sickle) is derived from its sickle shaped gametocytes. 
. 4.  P. ovale (Stephens- 1922)  
The parasite will cause ovale tertian malaria. Its name is 
derived from its oval shape and also the shape of the infected 
RBCs which is rendered oval 
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LIFECYCLE OF MALARIAL PARASITES 
They pass through 2 different hosts 18 
1. Man – The parasites residing inside the RBC and the liver cell reproduce 
by asexual method. Hence man is the intermediate host of the malarial 
parasite. 
2. Female anophelene mosquito – For the initiation of the mosquito cycle, 
sexual forms (male, female gametocytes) are first developed inside the 
human host. These are then transferred to their insect host where they 
develop further and are transformed to sporozoites. These sporozoites 
are infective to man. On account of this sexual method of reproduction, 
mosquito is the definitive host of the malarial parasites. 
ASEXUAL CYCLE IN HUMANS 
Human cycle starts with the introduction of sporozoites by the bite of an 
infected anophelene mosquito. It comprises of the following stages 
1. Pre erythrocytic schizogony 
Sporozoites undergo a developmental change inside the parenchymal 
cells of the liver in the man and get transformed into schizonts. This 
phase consists of only one generation of pre- erythrocytic schizont. It 
lasts for 
- 8 days in P. vivax 
- 6 days in P. falciparum 
- 9 days in P. ovale 
- 15 days in P. malariae 
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2. Erythrocytic schizogony 
During this phase, the parasite resides inside the RBC and develops 
through the stages of trophozoite, schizont and merozoite. Once the 
merozoites mature, they are released into the circulation. The release of 
merozoites, their destruction and the release of toxin are responsible for 
the clinical attacks of malaria. Each cycle lasts for 
- 48 hours in P. vivax, P. ovale, P. falciparum 
- 72 hours in P. malariae 
3. Gametogony 
After the parasites have undergone erythrocytic schizogony for a certain 
period, some of the merozoites develop in to gametocytes, which are 
capable of sexual function after leaving the human host. They develop 
inside the RBCs of the capillaries of spleen and bone marrow. Only the 
mature gametocytes are found in the peripheral blood. The maturation 
completes in about 96 hours. Gametocytes do not cause any febrile 
reaction in the human host. The individual who harbors the gametocytes 
is known as a “carrier” 
4. Exo- erythrocytic schizogony 
After the release of merozoites into the blood the initial tissue phase 
disappears completely in P.falciparum, where as in P. vivax, P. ovale 
and in P. malariae it persists in the form of a local liver cycle. The 
persistence of this late tissue phase is described as exo erythrocytic 
schizogony, which is responsible for the relapse of P. vivax, P. ovale 
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and P. malariae malaria. In the absence of fresh infection this phase 
forms the source of asexual parasites. 
SEXUAL CYCLE IN THE MOSQUITOES   
The sexual cycle of malarial parasite first starts from human host, by the 
formation of gametocytes. A female anopheles during its blood meal from an 
infected person ingests both the sexual and asexual forms of parasite. But it is 
only the mature sexual forms, which are capable of development, remains and 
the rest die immediately. It has been estimated that in order to infect a mosquito 
the blood of a human carrier must contain at least 12 gametocytes per cu.mm of 
blood. And the number of female gametocytes must be in excess of the number 
of male gametocytes. 
The gametocytes mature inside the stomach of the mosquito. They are 
ready then for fertilization. By a process called chemotaxis, one of the male 
gamete attaches with the female gamete. After fusion, the zygote is formed. 
This develops in 20 min to 2 hours after the blood meal. Next the zygote is 
transformed into a spherical mass surrounded by a cyst wall. This is called 
oocyst. As the oocyst matures, it develops into a large number of sickle shaped 
bodies known as sporozoites.  
After full maturation and after the 10th day of the infection the oocyst 
ruptures, releasing sporozoites in the body cavity of the mosquito. The 
sporozoites are distributed to various organs and tissues of the mosquito. They 
have a special predilection towards the salivary glands and ultimately reach a 
maximum concentration in salivary ducts. The mosquito at this stage is capable 
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of transmitting the infection to man. A single bite of mosquito is sufficient for 
this purpose. Different species of malarial parasites can develop in the same 
mosquito and this can give rise to mixed infection in man. 
EVOLUTION OF KNOWLEDGE OF MALARIA 18 
1847-49      --- Meckel & Virchow, first found out the presence of  
                         black pigment in organs with malarial infections 
1880  --- Laveran discovered the malarial parasite in an unstained           
                   preparation of fresh blood                                               
1883  --- Marchiafava used methylene blue for staining of malarial  
                        parasite 
             1885         --- Golgi demonstrated erythrocyte schizogony in benign  
                                     tertian malaria (Golgi cycle)         
1891 --- Romanowsky introduced the staining methods of malarial  
      parasite   
1898 --- Ross worked out mosquito cycle with parasite of human   
    malaria   
1934 --- Tissue phase of malarial parasite demonstrated in avian      
                               malaria 
1949         --- Shortt pre erythrocytic schizogony of P.falciparum in liver  
                       cells 
1954    --- Granham et al discovered the preerthrocytic schizogony of   
                     P. ovale                       
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TYPES OF MALARIA 
Depending upon the developmental stage in which the parasite is 
transmitted. 
1. Sporozoites induced malaria 
Injection of an emulsion of salivary secretion of the mosquitoes 
containing the sporozoites will induce infection. 
2. Trophozoite induced malaria 
a) Transfusion malaria 19. 
When infected patients (latent infection) are used as donors, 
malaria develops after blood transfusion.  
b) Congenital malaria 5 
Transmission of infection to the foetus in utero through some 
placental defects is called as congenital malaria. 
c) Malaria in drug addicts 
Seen in drug addicts who share syringes. 
  d) Therapeutic malaria 
Malarial infection is artificially induced for the treatment of 
neuro syphilis.  
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SPREAD OF MALARIA 
A human-to-human cycle transmitted by mosquito (human carrier) 
HUMAN CARRIER 
 
MOSQUITO 
 
HUMAN 
 
The factors responsible for the spread of malaria include the following (3) 
1. Source of malarial parasite (the presence of a gametocyte 
carrier)  
2. Existence of a suitable anophelene vector 
3. A susceptible person 
If this cycle or chain can be broken at any point, the occurrence of 
malaria can be prevented. 
PATHOGENICITY 
Each species causes a characteristic fever based on which the disease is 
designated as follows 
P. vivax                  --- Benign tertian malaria (vivax malaria). The fever recurs                  
      every third day since the cycle is 48 hrs. 
 15
P. malariae             --- Quartan malaria. The fever recurs every fourth day since  
   the   cycle is 72 hrs.  
P falciparum          --- Malignant tertian malaria (falciparum malaria). The fever 
     recurs every third day. It is also responsible for                       
pernicious malaria and Black water fever.      .                                                
fever. ‘Malignant’ because it is the most severe form of 
malaria and can be fatal. 
P. ovale                   --- Ovale tertian malaria. The fever recurs                  
       every third day since the cycle is 48 hrs. 
INCUBATION PERIOD 
The period between the introduction of sporozoites into the blood stream 
by the mosquito and the onset of symptoms is called the incubation period, 
which varies with different species as follows 18 
P. vivax & P. ovale   --- 10 to 17 days (average 15 days) 
P. falciparum             --- 8 to 12 days 
P. malariae                 --- 21 to 28 days (can be 30 – 60 days) 
CLINICAL FEATURES19,20 
In a typical case, there are series of febrile paroxysms, followed by 
anemia and splenic enlargement. 
1. Febrile paroxysms18 – it has 3 stages 
a. Cold stage – Lasts for 20 min to 1 hour 
b. Hot stage   - Lasts for 1 to 4 hours 
c. Sweating stage – Lasts for 2 to 3 hours 
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Total duration of febrile cycle is from 6 to 10 hours. (Varies with 
species of plasmodia) 
Febrile paroxysms synchronize with the erythrocytic schizogony of the 
malarial parasite. 
a. With a 48 hrs cycle  - Fever recurs every 3rd day (Tertian fever) 
b.  With a 72 hrs cycle - Fever recurs every 4th day (Quartan fever) 
c. Fever recurs at intervals of 24 hrs (Quotidian periodicity) 
2. Anaemia 
After a paroxysm, anaemia of a normocytic hypochromic type develops 
as a result of breaking down the RBCs during destruction of the parasites. 
3. Splenomegaly 
Enlargement of spleen is an important physical sign in malaria. In 
primary cases, the enlargement is so slight as to escape detection by palpation. 
After some paroxysms, and usually by 2nd week, it is definitely enlarged and 
palpable. 
COMPLICATIONS 
1. Cerebral malaria 
 It is the characteristic and ominous feature of falciparum malaria. It 
manifests as symmetric encephalopathy. Coma persists for more than 30 
minutes after generalized convulsions. It is 20% fatal in adults and 15% in 
children. 
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2. Acidemia/ Acidosis 
 The arterial pH is less than 7.25 (or) Plasma bicarbonate level is less 
than 15mmol/lit and venous lactate level is more than 5mmol/lit. It will 
manifests as labored deep breathing. 
3. Hypoglycemia 
 It is due to failure of hepatic gluconeogenesis and increase in the 
consumption of glucose by both the host and the malarial parasites. It is seen in 
children and pregnant women.  
4. Renal failure 
 It is common in adults. It is related to erythrocyte sequestration 
interfering with renal microcirculatory flow and metabolism. Manifests as urine 
output less than 400 ml in adults and there will be no improvement with 
rehydration. Serum creatinine will be more than 3mg/dl.  
5. Pulmonary odema 
 It is non- cardiogenic pulmonary edema. It is aggravated by over 
hydration. Mortality is more than 80%. 
6. Hypo tension / Shock 
 Systolic BP is less than 80mmhg in adults, core / skin temperature 
difference will be more than 100 C. 
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7. Disseminated intravascular coagulation 
 Bleeding from the gums, nose and gastrointestinal tract. 
8. Convulsions 
 There can be more than two generalized seizures / day. 
9. Jaundice 
 Mild haemolytic jaundice can be seen in infection with falciparum 
malaria. Serum bilirubin level is more than 3 mg/ dl. It is commonly seen in 
children. 
10. Anaemia 
 Due to the destruction of RBCs severe normocytic normochrmic anemia 
can occur. Hemoglobin level of less than 5 mg / dl can be seen. 
PATHOLOGY OF MALARIA 18 
There is hyperplasia of reticuloendothelial system resulting from 
increased activity in order to deal with the plasmodia and their products. 
(Haemozoin, toxins etc.) The haemozoin pigments are always found within the 
cells of the reticulo endothelial system 
  Parasitised erythrocytes fill the lumen of the capillaries of the internal 
organs. This is particularly seen in P.falciparum infection as the schizogony is 
mainly completed in the internal organs. Vascular changes consist of 
congestion and dilatation of sinusoidal vessels. Perivascular haemorrhages, 
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resulting from the damage to the capillary epithelium are seen in falciparum 
malaria. 
The spleen functions as a filter, removing the parasite as well as the 
product of their schizogony from the blood stream. The parasites are found in 
abundance in all stages of development in spleen, in all the forms of malaria, 
particularly in falciparum malaria. The organ is moderately enlarged. Malarial 
parasites and haemazoin pigments are actively phagocytosed in the spleen by 
macrophages, mainly by the cells of Billroth cords (Red pulp). The colour 
varies from slate-grey to black, depending on the amount of pigmentation. 
Liver is uniformly enlarged. The colour varies from chocolate-red to 
slate-grey or black depending upon the state of congestion and the amount of 
haemozoin pigment. The Kupffer’s cells are increased in number and their 
cytoplasms are filled with haemozoin pigment. The parenchymal cells of the 
liver lying in the central zone show fatty degeneration, atrophy and necrosis 
(centri-lobular necrosis). 
In acute cases, the marrow of the long bones undergoes very little 
change. In chronic cases, the upper and lower thirds of the long bones are 
reddish brown in colour. The vascular cellular tissue gradually replaces the 
yellow fatty marrow. Hyperplasia of reticulo endothelial cells which are laden 
with the haemozoin pigment and an erythroblastic reaction of the normoblastic 
type with some depression of myeloblastic activity. 
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CLINICAL PATHOLOGY 
Changes in the blood 19 
- Haemolytic anaemia (Normocytic, hypochromic type) 
- Leucocyte count is increased (with recurring paroxysms leucopoenia 
established) 
- Decreased neutrophils   
-  Increased monocytes    
-  Increased Serum Gamma globulin   
-     Increased ESR      
-     Elevated C- reactive protein, and other acute phase proteins  
CHRONIC EFFECTS OF MALARIA 19,21,36 
1. Tropical splenomegaly syndrome 
 Some young adults in zones endemic for P. falciparum malaria develop 
marked chronic splenomegaly. The spleen may enlarge over years to the weight 
of 3 to 4 kg, resulting in severe hypersplenism. 
2. Quartan malaria Nephrotic syndrome 
 This pattern of nephrotic syndrome in children in Sub-Saharan Africa 
have proliferative or sclerosing glomerulonephritis. A characteristic 
histological type is associated with endemic P.malariae infection, and 
immunoflurescence shows P. malariae antigen in the glomeruli.  
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3. Malaria and Malignant lymphoma  
 There is epidemiological evidence that high grade non- Burkitt’s, non- 
Hodgkins malignant lymphomas over represented in areas of Africa where P. 
falciparum malaria is holo endemic. 
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LAB DIAGNOSIS 
I. DEMONSTRATION OF THE PARASITE 22 
a. Examination of Thick and thin smear 
Microscopic demonstration of parasites in the blood smears, is the 
definitive method of diagnosis of malaria.  Examination of both thin and thick 
smears of blood is recommended. Thin film is useful for identifying the 
specific species and thick film is to detect the presence of the parasite. 
Specimen  
Blood film should be prepared directly from capillary blood. In case of 
EDTA anticoagulated blood, smears are to be made within an hour of 
collection of blood. Best time to take blood films is the midway between 
paroxysm of chills and fever. (When greatest number of intracellular organisms 
is present) 
Thin smear 
Wipe off the 1st drop of blood. Next drop of blood is touched with a 
clean dry glass slide near its end. The blood is spread evenly and thinly with 
the edge of a spreader slide. The film should stop before it reaches the edge of 
the slide. The thin, feathered end should occupy the central area of the slide. 
Thin smears are one blood cell in thickness. The film is dried in air. From this 
thin layer, the size of RBCs, and extra cellular forms can be easily visualized23 
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Thick smear 
 2 – 3 drops of capillary blood are directly placed from the finger prick 
to other end of the same slide as for thin smear and with the corner of another 
slide produce a square or circular patch of about 10mm diameter. Continuous 
stirring for 30 sec is necessary to prevent the formation of fibrin strands, which 
may obscure the plasmodia after staining. The optimum thickness of thick film 
is that which will just allow printed letters to be read through it. 
Staining 
Both the films are air-dried. The thick film is dehaemoglobinised by 
placing the film in distilled water. It is kept in a vertical position in a glass 
cylinder for 5 – 10 min, and then dried in air in upright position. Both the films 
are stained with Leishman’s or Giemsa stain. Other stains like Wright’s or 
Fildes stain or JSB (Jaswanth Singh and Bhattacharjee) stain may also be used. 
Examination 
All asexual erythrocytic stages, as well as gametocytes can be seen in 
peripheral blood in P. vivax, P. ovale and P. malariae infection, but in 
P.falciparum infection, only the ring form and gametocytes can be seen. 
Quantitation of the parasites 
The approximate number of parasites / thick film field (100*objectives) 
is as follows: 
+                  - 1 – 10 parasites /100 thick film field 
++               - 11 – 100 parasite/ 100 thick film field 
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+++             - 1 – 10 parasite / thick film field 
++++           - More than 10 parasites / thick film field 
b. Quantitative buffy coat 24-34 
Parasites can be concentrated by micro centrifugation using glass capillary 
tube and closely filling plastic insert. (QBC malaria blood tubes available from 
Becton Dickinson, - USA 23) 
QBC tube is specially prepared glass haematocrit tube, precoated 
internally with acridine orange stain and potassium oxalate. 
A volume of 55 – 65 micro liters of blood is collected from finger, ear 
and heal puncture and centrifuged at 12000 rpm for 5 min. RBCs containing 
malarial parasites are less dense than normal RBCs and concentrate just below 
the leucocytes at the top of the erythrocytic column.22 
The parasite contains DNA, but the mature RBCs do not contain DNA 
& RNA. Parasite DNA is detected by acridine orange stain and appear as bright 
specks of light among the non- fluorescing erythrocytes when the QBC malaria 
tubes are rotated under a special type of lens (Paralens UV microscope adapter, 
with a 60 X oil immersion objective 27 attached to an ordinary light 
microscope), almost all the plasmodia in the blood sample can be visualized. 
Advantages  
A negative test can be reported within a minute and positive result 
within few minutes. It is an easy method, reliable 24, faster (within 15 – 30 min),  
sensitive, and is as good as a thick film 25.  
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It is a qualitative screening test for species identification 31 and accurate. 
QBC paralens can perform a greater variety of tests, including Chlamydia, 
Filaria, Anti Nuclear Antibody (ANA), and Cyto MegaloVirus (CMV) etc. 
Quick and accurate blood cell count with 2 part differential count can be 
done. It gives very accurate platelet count for monitoring dengue patients. 
Disadvantages   
Quantitation of parasitemia relies on a subjective grading system. 
Expense is high. The events of blood filled tubes breaking or leaking in the 
centrifuge machine are other drawbacks 24. 
Equipment required and QBC tubes are expensive, unaffordable to 
public health services and small lab in developing countries 27. 
Howell- jolly bodies, artifacts such as cell debris and bacterial 
contamination may give false positive results. 
The tubes do not remain readable for more than a few days, and hence 
cannot be kept for record purpose. 
Examination 
Due to acridine orange, the malarial parasite stains green (DNA, RNA 
nucleus) and orange (RNA, cytoplasm). The tube is examined in the region 
between the RBCs and granulocytes and within the granulocytes and 
mononuclear cell layer, where parasites are most abundant 24. 
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An attempt was made to estimate the relative quantity of parasites in the 
specimens, using the Plus system. 
+                   - 1 parasite/ QBC field 
++                - 1 – 10 parasite/ QBC field 
+++              - 11 – 100 parasite/ QBC field 
++++            - 100 parasites/ QBC field 
QBC was found to be 100% sensitive for both P. vivax and P.falciparum 
and 100% specific for P.falciparum and 95% specific for P. vivax 28 
In some occasions, when the parasitemia is high, gametocytes, schizonts 
and trophozoites were widely dispersed within the entire span of the blood 
column, so it is necessary to scan through the whole blood column before 
giving a final report of a QBC test 29-34. 
c. Micro concentration technique 
Blood is collected in microhematocrit tube and centrifuged at high 
speed. The sediment is mixed with normal serum and smear is prepared. 
Although the positivity rate is increased by this method, there is change in 
morphology of the parasite. 
II. IMMUNODIAGNOSIS 
Serology cannot match the sensitivity of microscopic detection of 
malarial parasite, but assist the diagnosis of mild infection. These antibody 
tests include indirect fluorescent antibody (IFA) test, indirect 
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haemagglutination assay (IHA), ELISA and RIA  (Radio Immuno Assay). 
They are useful for epidemiological purpose. 
III. NEWER DIAGNOSTIC METHODS 
a. Rapid and Simple stick test 
This test is based on detection of monoclonal antibody against 
P.falciparum histidine rich protein 2 antigens (HRP-2). This test is based on 
antigen capture and has been incorporated in a dipstick format. Antibodies 
specific for P.falciparum, HRP – 2 are immobilized in the dipstick (test strip) 
when dipped in the blood. A solid pink line indicates positive test. This is very 
useful in treatment and diagnosis of drug resistant P.falciparum. 
b. Use of fluorescent dye 
Benzothiocarboxypurine (Fluorescent dye) intensely stains nucleic acid 
of malarial parasites after penetrating RBCs. The dye does not stain nuclei of 
WBCs. This is useful in field lab for mass screening, because of rapid staining 
and evaluation, but requires a fluorescent microscope. 
c. Detection of parasitic antigen 
Detection of malarial antigen by Radio Immuno Assay (RIA), DNA 
probes and Polymerase Chain Reaction (PCR) is under evaluation. PCR detects 
P.falciparum and P. vivax nucleic acids. In suspected mixed malarial 
infections, PCR detection system has got its importance undoubtedly. 
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DRUGS USED IN MALARIA35 
 The drugs used in malaria act at different stages of development of the 
malarial parasites. Depending upon the stage, they can prevent the attacks 
(prophylaxis), relieve the signs and symptoms (clinical curatives) or prevent 
relapses (radical curatives). 
1. Drugs used for causal prophylaxis (True prophylaxis) 
They are given in the pre- erythrocytic phase in the liver, which is the 
cause of malarial infection and clinical attacks. 
- Proguanil 
2. Drugs used for clinical and suppressive cure (Clinical curatives) 
 They act on the parasites in the erythrocytic stage. They are used to 
terminate the episode of malarial fever produced by the erythrocytic schizonts 
and alleviate the clinical symptoms and signs.  
 Fast acting      - Chloroquine, Quinine, Mefloquine, Atovaquone, Artemisinin  
 Slow acting    - Antimalarial antifolates and antibiotic compounds  
3. Drugs used to eradicate the parasites (Radical curatives) 
These drugs act in the exoerythrocytic stage and when given together 
with a clinical curative, will achieve total eradication of the parasites from the 
patients, thereby prevent the relapse. 
- Primaquine 
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4. Drugs used for preventing transmission 
They eliminate the male and female gametes of Plasmodia formed in the 
patient’s blood. 
a. From human to the vector 
           Chloroquine, Quinine – For P. vivax, P. ovale, P. malariae 
           Primaquine – P.falciparum 
       b. From vector to humans 
           Not yet known 
PHARMACOLOGY OF DRUGS USED IN MALARIA 
 Antimalarial drugs are used to prevent and treat clinical attacks of 
malaria. Some drugs completely eradicate the parasites from the patient’s body 
and reduce the human reservoir of infection. They attack the parasite at its 
various stages of life cycle in the human host. Antimalarials that act on 
erythrocytic schizogony are called erythrocytic schizonticides. Those that act 
on pre erythrocytic and exoerythrocytic stages in the liver are called tissue 
schizonticides. The drugs that kill gametocytes in blood are called as 
gametocides. 
Quinine  
  Quinine was the first drug given for malaria since 1633. A powder of 
Cinchona “given as a beverage, cures the fevers and tertians” was used in 
South America. 
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 In 1640, Quinine was used in Europe for the treatment of fever. In 1820 
it was isolated from cinchona powder and the extract was used for malaria 2. It 
gets concentrated in the acidic vacuoles of the blood schizonts and causes 
pigment changes. It will inhibit polymerization of heme to hemazoin. Free 
heme or heme- quinine complex damages parasite membrane and kills it.  
Quinine was the first drug used for falciparum malaria especially in 
severe cases. It can be given in the dose of 600 mg three times a day for three 
days. It is a rapidly acting drug. Half- life is about 11 hrs. It is effective against 
blood schizonticide. It is also a gametocidal drug. It is used in severe 
falciparum malaria and in babesiosis. It can produce adverse effects such as 
cinchonism, hypersensitivity reactions, hypoglycemia, hypotension, and black 
water fever. 
Chloroquine 
 It was discovered in 1934, and named Resochin. The antimalarial 
research was done in United States during World War II, and by the year 1943 
it was synthesized and tested for its activity in humans. This is discussed in 
detail later. 
Mefloquine 
 It is a fluorinated 4 – quinoline methanol compound. It is given by oral 
route (There is no parentral preparation for this drug). Peak plasma 
concentration of mefloquine is within 18 hrs. It is highly protein bound. It is 
slowly excreted via feces for 20 days. It is a strong erythrocytic schizonticide 
for P.falciparum and for P. vivax but not for severe infections. Epigastric pain, 
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headache, arrhythmia, bradycardia are the common side effects. It is safe in 
children and pregnant women. It is used in both the treatment of falciparum and 
vivax infection and for chemoprophylaxis. For falciparum infection it is given 
in the dose of 25mg/kg. It is splitted into 2-3 doses on the same day. In 
prophylaxis, it can be given in the dose of 5mg /kg /week. 
Amodiaquine 
  It is a 4 aminoquinoline with a similar mode of action as chloroquine. It 
is more active against resistant isolates of P.falciparum. It can be given in the 
dose of 25-35 mg /kg over three days. 
Primaquine 
  It is an 8- aminoquinoline used for hypnozoites of P. vivax and the 
gametocytes of P.falciparum. It is well absorbed and cleared by hepatic 
clearance. Elimination half-life is about 17 hours. Nausea, vomiting and 
abdominal discomfort is common with higher doses. The principal toxicity of 
primaquine is haemolysis in patients with G6PD deficiency. It is used in radical 
cure of relapsing malaria. It is given in the dose of 15mg (0.25mg/kg/day) for 
two weeks. 
Proguanil/ Chlorproguanil 
These are the safest of all malarial drugs. They act by dihydro folate 
reductase (DHFR) inhibition. They are well absorbed orally. Parent compounds 
are eliminated very slowly. Mouth ulcers and hair loss are the common side 
effects. They are used as prophylactic drugs. It is given in the dose of 200mg/ 
day. 
 32
Pyrimethamine 
 It is also a dihydrofolate redutase inhibitor. It is used widely in 
combination with long acting sulfonamides like sulfadoxine and sulfalene. It 
inhibits the development of mature trophozoite stage of asexual parasite, in 
addition to having pre- erythrocytic and sporontocidal activities. It is well 
absorbed and is eliminated over several days (half life is 3 days) allowing 
single dose treatment. It is given as 1.25-mg /kg single oral dose. 
Halofantrine 
  It is a 9-phenanthrene methanol. It is more potent than quinine and 
mefloquine.  It is poorly absorbed. Fatty food increases its absorption. It is 
extensively distributed and cleared largely by hepatic biotransformation. The 
elimination half-life is 1-3 days. Vomiting, dizziness, weakness and dysphoria 
are the common side effects. It is used for the treatment of uncomplicated 
multidrug resistant falciparum malaria. The dose is 8mg/kg three times a day 
and repeated one week later in non- immune patients 36. 
Qinghaosu 
  It is also known as artemisinin. It is sesquiterpene lactone peroxide 
extracted from the leaves of shrub Artemesia annua. Two derivatives are 
widely used, the oil soluble methyl ether, artemether and the water-soluble 
hemisuccinate derivative artesunate. These are rapidly acting of all known anti 
malarials. They also have a broad window of anti malarial effect against ring 
forms to the mature trophozoites. They produce rapid parasite clearance and are 
very safe. Arteether is a very similar compound to artemether. It is the oil 
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soluble ethyl ether given by intramuscular injection. Artelinic acid 36 is a water-
soluble second-generation compound under development. They are well 
absorbed and have rapid elimination with half-lives varying from minutes 
(artesunate) to hours (arteether and artemether).  
Antibacterials with antimalarial activity 
1. Sulphonamides / Sulphones 
 They will inhibit plasmodial folate synthesis by competing with the 
enzyme dihydrofolate reductase. They are usually combined with 
pyrimethamine or the antimalarial biguanides.  
2. Tetracyclines 
 They are consistently active against all the species of malaria. 
3. Macrolides 
 They are active in vitro. Azithromycin has been evaluated as 
prophylaxis and Clindamycin has proved effective in the treatment of 
falciparum malaria. 
4. Rifampicin 
 It is a weak antimalarial in vivo. It acts very slowly hence combined 
with rapidly acting agents. 
5. Fluoroquinolones 
 They have some antimalarial activity, but not yet proved. 
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CHLOROQUINE 
History 
   It is the drug of choice for both treatment and chemoprophylaxis of 
malaria since 1940 37. It is one of the large series of 4 aminoquinolines, 
investigated as part of the extensive programme of antimalarial research in 
United States during World War II. Beginning in 1943, thousands of these 
compounds were synthesized and tested for their activity. It was synthesized 
and studied under the name of Resochin by Germans as early as 1934. 
Chemistry 
It closely resembles the obsolete 8 aminoquinoline antimalarials, 
Pamaquine and pentaquine. It contains the same side chain as quinacrine, but 
differs from this antimalarial in having a quinoline instead of an acridine 
nucleus and in lacking the methoxy moiety. 
The d, l, forms of chloroquine have equal efficacy in duck malaria, but 
the “d” isomer is less toxic than “l” isomer in mammals. 
The chlorine atom attached to position 7 of the quinoline ring confers 
the greatest antimalarial in human malaria 2.  
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PHARMACOLOGICAL EFFECTS 
Antimalarial actions 
  It is highly effective against erythrocytic forms of P. vivax, P. ovale, P. 
malariae and chloroquine sensitive strains of P.falciparum. It exerts activity 
against gametocytes of the first three plasmodial species but not against those 
of P.falciparum. The drug has no activity against latent tissue forms of P. vivax 
or P. ovale and cannot eradicate infections with these species. Chloroquine is 
not active against parasites in the liver. 
Other actions 35 
   Chloroquine has direct toxic action against trophozoites of E. histolytica, 
and it reaches high concentration in the liver, hence used to treat hepatic 
amoebiasis. 
  Chloroquine and Hydroxy chloroquine have been used to treat a variety 
of chronic diseases, because both the alkaloids concentrate in lysosomes and 
have anti-inflammatory properties. Hence used in Rheumatoid arthritis, 
Systemic Lupus Erythematosis, Discoid lupus, sarcoidosis, photosensitivity 
diseases such as porphyria cutanea tarda and severe polymorphous light 
eruptions. 
Mechanism of action 
 Malarial parasites survive by digesting hemoglobin in the acidic food 
vacuoles of host RBCs, a process that generates free radicals and heme 
(Ferriprotoporphyrin IX) as highly reactive by-products. 
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  After nucleation aided by histidine rich proteins and lipids, heme 
polymerizes into an insoluble unreactive malarial pigment termed haemozoin. 
Quinoline blood schizonticides are weak bases and they get concentrated 
in the acidic food vacuoles of susceptible plasmodia. They increase the pH of 
the food vacuoles, prevent the oxidation of heme to hemazoin, and disrupt its 
non- enzymatic polymerization to haemozoin. Hence heme remains inactivated 
and kills the parasites by causing oxidative damage to parasite membranes.  
Pharmacokinetics 
Chloroquine is well absorbed from gastrointestinal tract, and rapidly 
from intramuscular and subcutaneous routes. Drug distributes slowly into a 
very large apparent volume (over 100 – 1000 l /kg) of distribution. This is due 
to extensive sequestration of the drug in tissues like liver, spleen, kidney, lung, 
and melanin containing tissues and to a lesser extent brain and spinal cord. 
  It moderately binds (60%) with plasma proteins and undergoes 
biotransformation via the hepatic cytochrome P450 system to 2 active 
metabolites – Desethyl chloroquine and Bisdesethylchloroquine. These 
metabolites reach concentration in plasma to 40% & 10% of that of 
chloroquine respectively. 
Excreted in urine with initial half-life of 3 to 5 days, but terminal 
elimination half-life is 2 months. The renal clearance of chloroquine is about 
half of its systemic clearance. Unchanged chloroquine and its metabolites 
account for more than 50% and 25% of urinary drug products respectively. The 
renal excretion of both the products is increased by acidification of the urine. 
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Chloroquine is given mainly orally. It is also given either by slow 
intravenous infusion or small divided doses by subcutaneous or intramuscular 
routes. It is safer when given orally, because the rate of distribution and 
absorption are more closely matched. Peak plasma level is achieved in about 3 
– 5 hrs after oral route. 
  It is more potent and less toxic and it needs to be given only once 
weekly as a suppressive agent compared to quinine. Chloroquine is known to 
cause vomiting. But when given along with meals, vomiting will be reduced 
significantly. It is safe in pregnant women and children 38. 
DOSAGE OF CHLOROQUINE 39,40 
Dose of chloroquine 
As base (Each 250 mg tablets contain 150 mg base 
& each 5 ml suspension contains 50 ml base) Age in years 
1 st dose 2 nd dose 3 rd dose 4 th dose 
0-1 75 mg 75 mg 
 
37.5 mg 37.5 mg 
1-5 150 mg 150 mg 
 
75 mg 75 mg 
5-9 300 mg 150 mg 
 
150 mg 150 mg 
9-14 450 mg 225 mg 
 
225 mg 225 mg 
>14 600 mg 300 mg 
 
300 mg 300 mg 
 
 The first dose is given as a loading dose followed by second dose after 8 
hours, third dose on second day and third dose on fourth day. 
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TOXICITY & SIDE EFFECTS 
If taken in proper dose chloroquine is an extraordinarily safe drug. 
1. In therapeutic doses  
Oral route – vomiting, headache, visual disturbances, and urticaria. 
On prolonged treatment - 
  Headache, blurring of vision, diplopia, confusion, convulsions, lichenoid 
skin eruptions, bleaching of hair, widening of QRS interval, and T wave 
abnormalities. 
2. Acute chloroquine toxicity 
  Frequently encountered with high doses administered too rapidly by 
parenteral routes. Toxic manifestations are, 
         CVS     - Hypotensive shock, vasodilatation, suppressed myocardial 
function, cardiac arrhythmias, and eventual cardiac arrest. 
         CNS    - Confusion, convulsion and coma 
3. High daily doses (> 250mg) for non- malarial conditions 
When used for the treatment of diseases other than malaria, results in 
irreversible retinopathy and ototoxicity. 
PRECAUTIONS & CONTRAINDICATIONS 
 It is not used in persons with epilepsy, myasthenia gravis because it 
itself can induce epileptic attacks. 
 39
Given cautiously in hepatic, severe gastrointestinal, neurological or 
blood disorders. 
Can cause hemolysis in patients with G6PD deficiency. 
Gold derivatives and Phenylbutazone should be avoided along with 
chloroquine since all the three can produce dermatitis. 
 It should not be combined with mefloquine to avoid convulsions, and 
with amiodarone and halofantriene to avoid ventricular arrhythmias.  
RESISTANCE 
Resistance to chloroquine is common among strains of P.falciparum, but 
occurs also for P. vivax in many parts of the world 40,42 
  The resistance is reported to be caused by relatively reduced levels of 
chloroquine in food vacuoles due to difference in plasmodial uptake and 
transport of chloroquine. The resistant strains develop the ability to cause 
efflux of chloroquine, so that the preventive action of chloroquine on heme 
metabolism is inhibited.  
2 homologous mdr genes (multi drug resistant genes) P.fmdr.1 & 
p.fmdr.2 in plasmodium falciparum have been identified 2.  
CURRENT TREATMENT19 
  When a patient from an endemic area presents with fever suggestive of 
malaria, smear should be prepared to confirm the diagnosis and identify the 
species of infecting parasites. Patients with severe malaria or those unable to 
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take oral therapy should receive parentral antimalarial therapy. Chloroquine is 
the treatment of choice for the “benign malaria” (P. vivax, P. ovale, P. 
malariae). 
Treatment of uncomplicated malaria 
1. Infections due to P. vivax, P. ovale, P. malariae, and sensitive strains of 
P.falciparum should be treated with oral chloroquine. 
- Chloroquine (base) 600 mg stat followed 8 hours later by 300 mg, and 
after that 300mg once daily for days 2 & 3. (Total dose of 25 mg of base/kg). 
Or 
- Amodiaquine (base) 600 mg followed by 200 mg (base) on the day                            
one after 8 hours and, 400 mg once a day for days 2 & 3. 
Or 
 - Quinine (salt) 300 mg, 6 tablets daily for three days, followed by 4 
tablets daily for the next 5-10 days 
2. Chloroquine resistant falciparum can be treated with, 
 - Sulfadoxine/ Pyrimethamine (25/1.25mg/kg) 3 tablets (single dose) 
followed by quinine 600 mg, orally three times a day for 2 days. 
Or 
 - Quinine 600mg three times a day & Tetracycline (250 mg four times a 
day for 7 days or Doxycycline. (Tetracyline and Doxycycline cannot be given 
to pregnant women and to children less than 8 years of age) 
Or 
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 - Mefloquine 750 mg orally, repeated after 6 hours (given in a total dose 
of 25mg  / kg) 
Or 
  - Mefloquine & Artesunate, or Artemether (4mg /kg /day for 3 days) 
Or 
 - Artemether & Lumefantrine 
Or 
 - Atovaquone & Proguanil 
                All the drugs are well tolerated, and given in 3 days regimen. 
3. To eradicate persistent liver stages and prevent relapse 
- Primaquine (0.3 mg base /kg /day, 15 mg base, adult dose) for 14 days 
to patients with P. vivax, P. ovale infections after tests for G6PD deficiency 
have proved negative. If there is mild G6PD deficiency, Primaquine should be 
given in the dose of 0.6 mg base /kg (45 mg maximum) once weekly for 8 
weeks. 
Treatment for severe malaria 
1. Chloroquine sensitive P. falciparum cases 
  - Chloroquine 10 mg base/ kg infused intravenously at a constant rate 
over 8 hours followed by 15 mg base/ kg over 24 hrs. 
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2. Chloroquine resistant P.falciparum 
  - Quinine is the most widely used drug for the treatment of severe    
malaria worldwide  
  - Quinine dihydrochloride 7mg salt/ kg infused over 30 minutes 
followed by 10 mg /kg over 4 hrs.  Maintenance dose – 10 mg salt /kg infused 
over 2-8 hrs at 8 hours intervals. 
Or 
  - Artemether 3.2 mg/kg stat intramuscularly followed by 1.6 mg/kg  
                               at 24 hour intervals 
Or 
  - Artesunate (2.4 mg/kg stat intravenously or intramuscularly followed 
by 1.2 mg /kg at 12 and 24 hours then 1mg /kg daily) 
Other supportive measures like anti histamines, antipyretics, analgesics, 
antiemetics, and anti ulcer treatment is given according to the individual 
patients need. 
TREATMENT FAILURE   
Many factors contribute to treatment failure, including incorrect dosing 
regimen, drug interactions, poor or erratic absorption and drug resistance (8). 
They also contribute to the development and intensification of true drug 
resistance through increasing the likelihood of exposure of parasites to sub 
optimal drug levels. 
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RESISTANCE 
The resistance can be of two types.  
a. Drug resistance 
b. Vector resistance 
DRUG RESISTANCE 
The WHO developed the following grading system to describe the 
relative degrees of resistance of strains of P. falciparum to chloroquine 41. 
1. R I resistance is defined as clearance of asexual parasitemia, 
followed by recrudescence 
2. R II resistance is defined as marked reduction of asexual parasitemia, 
but no clearance. 
3. R III resistance is defined as no marked reduction in parasitemia. 
Biological influences on resistance 36,39 
1. Factors that decrease immune system in clearing parasite (malnutrition, 
patients on anti HIV treatment, immunosuppressed state etc) 
2. Certain combination of drug resistant parasites and vector species enhance 
resistance. 
3. Many antimalarial drugs in current usage are closely related chemically and 
development of resistance to one facilitates development of resistant to 
others. 
4. Genetic plasticity allows the parasite to rapidly adapt to a new drug.  
5. Using drugs with long half life (because of prolonged elimination periods) 
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Pharmacological influence on resistance 
1. Over all drug pressure 
2. Inadequate drug intake (poor compliance or inappropriate dosing 
regimens) 
3. Reliance on presumptive treatment can facilitate. 
MECHANISM OF DRUG RESISTANCE 
  Resistance appears to occur through spontaneous mutations that confer 
reduced sensitivity to a given drug or class of drugs. Resistance is more 
common with falciparum malaria.  
  It is believed that resistance of P.falciparum to chloroquine is related to 
an increased capacity for the parasite to expel chloroquine at a rate that does 
not allow chloroquine to reach levels required for inhibition of heam 
polymerization. This chloroquine efflux occurs at a rate 40-50 times faster 
among resistant parasites than sensitive ones 36. This efflux mechanism is 
similar to that of found in multidrug resistant mammalian tumour cells, and is 
mediated by an ATP requiring transmembrane pump, P.glycoprotein 10,15,36,37. 
Chloroquine resistance in P.falciparum is associated with multiple unlinked 
mutations in the digestive vacuole transmembrane protein PfCRT 6 
  Specific gene mutations encoding for resistance to both Dihydropteroate 
synthase and Dihydrofolate reductase have been associated with varying 
degrees of resistance to antifolate combination drugs. P. vivax is intrinsically 
relatively insensitive to these drugs 36. 
 45
  Single point mutation in cytochrome – b gene causes resistance to 
atovaquine 14. Factors that have contributed for antimalarial drug resistance 
include vector and parasite biology, pharmacokinetic properties of the drugs, 
and economic status of the patient. 
TO REDUCE THE INCIDENCE OF RESISTANCE          
1. Reducing the over all drug pressure 
2. Improving the prescribing, follow up and patient compliance. 
3. Combination therapy 19  
To overcome drug resistance, many new antimalarial drugs have been 
discovered by adopting several strategies ranging from, 7 
1. Minor modification of existing agents to the design of novel agents that 
acts against new targets.  
2. Combining previously effective drugs with compounds that reverse 
parasite resistance offers another approach to chemotherapy. 
3. Combining 2 or more drugs with different modes of action 
VECTOR RESISTANCE 
Female anopheles mosquito transmits malaria. This is usual and 
common mode of transmission. Over 60 species of mosquitoes act as vectors. 
Out of them 45 are present in India. The important vectors in India include An. 
Culcifacies, An. Stephensi, An. phillippiensis, An. minimus, An. fluviatilis, 
An. sundaicus, An. maculatus and An. annularis. An. subpicters has also been 
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incriminated as vector in certain areas. The vectors of major importance are 
An. Culcifacies in rural areas and An. Stephensi in urban areas. 22 
Vector control 
Vectors can be controlled in 2 ways. Using Larvicides, which acts 
against Larva (Paris green, pyrethrum, Organochlorides (not safe) and 
organophosphorous (safe) compounds), and Imagocides, which acts against 
adult mosquito 36 (DDT (2,2 bis – (p-chlorophenyl)- 1,1,1- trichloroethane), 
chlorinated hydrocarbons, gamma benzene hexachloride (gamma HCH), 
dieldrin, Pyrethrins, pyrethroids, Anticholinesterases organophosphorous 
compounds).     
Resistance 
Malathion and fenithrothion are organophosphates insecticides, which 
are being used with increasing frequency for malaria control following the           
development of vector resistance to DDT 3 
Because of resistance to the newer larvicidals, the old method such as 
oiling the collections of standing water or dusting them with Paris green is 
used.     
PROPHYLAXIS 
Personal protection against malaria includes 19,36 
      1. Suitable clothing of exposed skin surfaces. 
2. Application of permethrin or delmethrin to clothing or the use of insect                 
repellants containing Diethyl toluamide (DEET) (10-35%) 
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3. Insecticide impregnated (Permethrin, delamethrin) bed nets & other     
materials 
4. Houses can be mosquito proofed by housing wire mesh grilles over 
windows, and designed in such a way as to discourage mosquito ingress. 
Administration of chemoprophylaxis to high- risk groups like 19 
- Pregnant women traveling to endemic areas. 
- Children between the ages of 3 months to 4 years in areas where    
malaria causes high childhood mortality. 
- Children born to non-immune mothers in endemic areas and  
- Travelers who are going to an endemic areas.  
  Anti malarial prophylaxis should be started from at least 1 week before 
departure and continued till 4 weeks after the traveler has left the endemic area 
except if atovaquine- proguanil or primaquine has been taken can be 
discontinued 1 week after departure from the endemic areas.  
 48
The drugs used are 19 
Drug Use Adult dose Child dose 
Mefloquine In areas where 
chloroquine  
resistant malaria is 
reported 
228 mg base 
(250 mg of 
salt) 
Orally, once a 
week 
< 15 kg- 4.6mg base/kg 
(5 mg of salt)  
15-19 kg- ¼ tab /week 
20-30 kg- 1/2 tab /week 
31- 45 kg- 3/4 tab 
/week 
> 45kg 1tab /week 
Doxycycline Alternative to 
mefloquine or 
atovaquine-proguanil 
100mg orally, 
once/day 
> 8 years age-2 mg /kg 
per day 
Maximum dose 100 mg 
/day 
Atovaquine-
proguanil 
Alternative to 
mefloquine or                               
doxycycline 
250/100mg 
orally,
once/day 
11- 20 kg - 62.5 mg /25 
mg 
21-30 kg- 125 
mg/50mg 
31-40kg-187.mg / 
75mg 
> 40 kg- 250 /100mg 
Chloroquine Used in areas where 
chloroquine – 
resistant malaria has 
not reported 
300 mg of 
base orally, 
once a week 
5 mg/kg of base orally, 
once a week. Maximum 
dose 300 mg base 
Proguanil Along with 
chloroquine, as 
alternate to 
mefloquine or 
doxycycline 
200 mg orally, 
once daily 
with weekly 
chloroquine 
< 2 years- 50 mg /day 
2-6 years- 100mg /day 
7-10 years- 150mg /day 
> 10 years- 200mg /day 
Primaquine For travelers only 
after testing for 
G6PD deficiency, 
post exposure 
prevention for 
relapsing malaria or 
prophylaxis  
Post exposure- 
15mg base 
(26.3mg of 
salt) once 
daily for 14 
days 
Prophylaxis- 
30mg of base 
daily 
0.3mg base /kg (0.5mg 
of salt/kg) orally, once 
a day for 14 days 
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USE OF VERAPAMIL IN MALARIA 
Many drugs have been shown to reverse the resistance of P.falciparum 
to chloroquine in vitro. Among them the antihypertensive, Verapamil is proved 
as an effective chemosensitizer.   
In 1987, Martin et al has reported about the reversal of chloroquine 
resistance in P.falciparum by verapamil 8.  Here the chloroquine resistance was 
reversed in vitro and in animal models by co- administering with verapamil. 
In 1988, another study done by Bitoni et al has revealed reversal of 
chloroquine resistance by verapamil and desipramine 17.  
  In 1990, Watt.g et al proved that verapamil and desipramine caused a 
dose dependant increase in the accumulation of chloroquine within human and 
mouse hepatocytes 10.  
In 1991, Ohsawa k, et al has shown the reversal of chloroquine 
resistance by verapamil, in human and rodent malarial parasites. They proved 
the ultra structural changes (swelling of the food vacuoles) associated with 
reversal of chloroquine resistance by verapamil in P.chabaudi 42. 
In 1994, Bray PG, et al proved the relationship of global chloroquine 
transport and reversal of resistance in P.falciparum 16. 
  In 1995, Martiney et al proved that verapamil increases the net uptake 
and cytotoxicity of structurally diverse hydrophobic molecules in many 
multidrug resistant mammalian cell lines. The resistance reversal mechanism 
may be an increase in the amount of chloroquine present in erythrocytes 
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infected with the infected parasites. In short time incubations verapamil was 
found to increase net chloroquine accumulation in erythrocytes with both 
chloroquine sensitive and resistant organisms.  It was also found that verapamil 
is also toxic 11 for trophozoites. 
In 1996, Rabinovich et al revealed the reversing action by in vivo 
experiments using P. berghei model, resistant to chloroquine 13. 
In 1998, Alovelande J described the interaction of two calcium channel 
blockers, verapamil and fantofarone in reversing chloroquine resistance in 
P.falciparum 21. 
In 1998, Jean bikii et al investigated the assessment of three in vitro tests 
and in vivo test for chloroquine resistance in P.falciparum clinical isolates 14. 
In  1999, Kaminsky R. et al investigated mutidrug – resistant and as well 
as susceptible Trypanasoma brucei brucei. Verapamil showed antitrypanosomal 
activity against the both 43. 
In 2003, David C warhurst showed the polymorphism in the 
P.falciparum chloroquine – resistance transporter protein, links verapamil 
enhancement of chloroquine sensitivity with the clinical efficacy of 
amodiaquine15. It was demonstrated that inhibition of calcium influx during cell 
activation by blocking voltage regulated Ca channels. 
All these studies indicate that verapamil would be effective in 
chloroquine resistant malaria. 
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VERAPAMIL  
  It is the first drug used clinically as a calcium channel blocker. Hass and 
Hartfelter reported in 1962 that verapamil has a coronary vasodilator effect and 
possess negative inotropic and chronotropic effect. In 1967 it was proved that 
negative inotropic effect was due to inhibition of excitation contraction 
coupling and the mechanism involved is the reduction of movement of calcium 
into cardiac myocytes.  
Chemistry 
 
 
 
 
It belongs to a phenylalakylamine group of calcium channel blocker. It 
is prescribed as a racemate “l” verapamil, which is more potent Ca2+ channel 
blocker than “d” verapamil. 
Pharmacokinetics 
Peak effect of verapamil occurs within 15 min of its intravenous 
administration. With oral therapy “l” verapamil under goes more extensive first 
pass metabolism. For this reason, a given concentration of verapamil prolongs 
PR interval to a greater extent when the drug is administered intravenously. 
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Verapamil can cause gastro esophageal reflex. Constipation can occur with oral 
verapamil (22). 70 – 98% bound to plasma proteins. 
Its elimination half-life is widely variable. N- methylation of verapamil 
results in production of norverapamil, which is biologically active, but much 
less potent than parent compound. Half-life is 10 hrs. In patients with hepatic 
disease the half-life increases to 14 – 16 hrs because of increased volume of 
distribution. It can be given in the dose of 80- 160 mg orally for every 8 hours. 
Verapamil competitively blocks the drug transporter, ‘p’ glycoprotein 
10,15,36.37
. Both the renal and hepatic disposition of digoxin occurs via the 
transporter. So verapamil inhibits the elimination of digoxin and other drugs 
that are cleared from the body by P – glycoprotein. 
Pharmacodynamics 
Verapamil binds with the transmembrane segment 6 of domain IV in 
alpha1.subunit of L type calcium channel. The drug acts from the inner side of 
the membrane and bind more effectively to channels in depolarizing 
membrane. Binding of the drug reduces the frequency of opening in response 
to depolarization. It results in marked decrease in transmembrane calcium 
current associated with smooth muscle with a long lasting relaxation. 
It is a potent coronary vasodilator; it suppresses cardiac contractility, 
suppresses the SA node automaticity, suppresses AV node conduction, and 
reduces the myocardial oxygen demand.
 
It lowers BP by relaxing arteriolar smooth muscle and decreasing 
peripheral vascular resistance. As a consequence of a decrease in peripheral 
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vascular resistance it evokes baroreceptor mediated sympathetic discharge. But 
tachycardia induced by this drug is minimal or sometimes absent, because of 
the direct chronotropic effect. 
Precautions & Contraindications 
Re-entrant Supra ventricular tachycardia (SVT) and nodal arrhythmias 
(Wolf Parkinson White Syndrome 35) are susceptible to verapamil, but it should 
not be used because of risk of increased ventricular rate due to reflex 
sympathetic stimulation and reduction of effective refractory period (ERP) of 
the bypass tract in some cases. 
 Intravenous verapamil with beta-blocker is contraindicated, because it 
has increased propensity for AV block or severe depression of ventricular 
function. 
In patients with ventricular tachycardia, intravenous injection of 
verapamil has precipitated ventricular fibrillation and therefore contraindicated. 
It is not recommended for digitalis toxicity, because additive A-V block can 
occur. It is contraindicated in partial heart block and sick sinus syndrome. 
Uses 
1. Paroxysmal supra ventricular tachycardia 
2. To control ventricular rate in Atrial fibrillation and Atrial flutter.  
3. In hypertrophic cardiomyopathy it will improve the left ventricular out 
flow obstruction and symptoms of the patients. 
4. Prophylaxis of migraine headaches.  
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METHODOLOGY 
STUDY CENTRE 
  The study was conducted in the Department of Medicine, Government 
Stanley Medical College Hospital, Chennai. 
STUDY DESIGN 
Prospective, Randomized double blind control clinical study. 
STUDY PERIOD 
From July 2005 to December 2005  
ETHICAL COMMITTEE APPROVAL 
 Study was conducted only after getting approval of the institutional 
Ethics committee. A copy of the approval is enclosed in the Annexure I 
SELECTION OF PATIENTS 
 INCLUSION CRITERIA 
Patients who fulfilled the following criteria were included in the study. 
- Patients diagnosed to have malaria by QBC method 
- Both the sexes 
- 15 – 60 years age 
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EXCLUSION CRITERIA 
Patients who had any of the following were excluded from the study. 
- Children < 15 years 
- Pregnant or lactating mothers 
- Those with known cardiac diseases (Hypertension, Coronary artery 
diseases, Bradycardia and conduction defects) 
- Diabetes and other associated illnesses. 
METHODOLOGY 
Sixty patients with QBC positive malaria were enrolled in the study. All 
the 60 patients were admitted in the Medicine ward. They were well informed 
about the study. Written consent was obtained from all of them. 
  Patients name, age, sex, residence, income, and locality were noted. 
Then the detailed history about the fever (duration, chills, rigor, whether 
continuous or intermittent), vomiting, abdominal pain, headache, and loss of 
appetite were recorded. 
General and systemic examinations were done. Temperature, pulse rate, 
blood pressure were recorded 4th hourly. And the patient was examined for 
anemia, Jaundice, splenomegaly and hepatomegaly. 
 After the clinical examination the following lab investigations were 
done. 
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1. Hematological investigations: 
- Hemoglobin 
- Total Count 
- Differential Count 
- Erythrocyte Sedimentation Rate 
- Peripheral smear for Malarial Parasite 
2. Urine examination 
- For Red Blood Cells (RBCs) along with the routine examination. 
3. Other investigations 
- Electrocardiogram (ECG) 
- Ophthalmic examination. 
A copy of the proforma is enclosed in Annexure II 
TREATMENT  
After the pre-trial investigations each patient was randomly allocated to 
either one of the 2 groups namely A & B.  
  Patient in-group A received the standard chloroquine therapy (600mg as 
first dose and after 8 hours 300mg, followed by 300 mg after 24 hours then 
another 300 mg after 48hours) along with symptomatic treatment. 
  Patient in-group B received in addition to chloroquine, 40mg of 
verapamil orally 2 hours after the administration of chloroquine. The drugs 
were given to the patient by the investigator personally. Since verapamil is an 
anti hypertensive drug, blood pressure and pulse rate were recorded 4th hourly. 
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   Each patient was examined 4th hourly for improvement in signs & 
symptoms (fever, chills, rigor, blood pressure, vomiting and abdominal pain) 
using the under mentioned parameters. 12th hourly QBC was done to know the 
rate of clearance of parasitemia. 
EVALUATION 
The following evaluating parameters were recorded. 
1. Time taken for the body temperature to become normal. 
2. Disappearance of symptoms like chills and rigor. 
3. Time taken for clearance of parasitemia. 
4. Reduction in splenomegaly. 
5. In addition, all the patients were subjected to the same pre-trial 
investigations and any change in the results was suitably analyzed. 
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RESULTS 
The double blind randomized control trial was undertaken to study the effect 
of verapamil in facilitating the action of chloroquine in malaria. Efficacy of the 
treatment was analyzed by using the parameters. The results were analyzed by 
Pearson Chi square test and Student t test and the P< 0.01 was considered significant. 
  It was observed from the above study that verapamil has a beneficial 
effect in malaria. Though both the groups got clinically cleared of malaria, the 
patients who were given verapamil had an easier relief and very faster 
clearance of parasitemia. All the patients who were included in the study 
completed their study. There were no dropouts. No one had vomiting or visual 
disturbances. And patients who received verapamil did not have any significant 
bradycardia or hypotension. 
Table 1      COMPARISON OF DEMOGRAPHIC PROFILE 
Control group Study group 
S. No Character 
Mean                SD Mean                 SD 
1 Age 26.40 12.05 
 
23.23 9.93 
2 Sex 24 Male 
(80%) 
6 Female 
(20%) 
 27 Male 
(90%) 
3 Female 
(10%) 
 
3 Residence 18 From 
Slum (60%)  
12 From 
other areas 
(40%) 
 
 14 From 
Slum (46.7%) 
16 From 
other areas 
(53.3%) 
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The mean age in control group was 26 years and in study group was 23 
years. Among the 60 patients enrolled in the study, 51 were males and 9 were 
female patients. Even in random allocation the number of male patients who 
entered the study was high in both the groups. The number of patients from 
slum and from other areas was equally distributed. There was no statistical 
significance in the residence 
Table 2   COMPARISONS OF CLINICAL FEATURES 
Group 
Control (30) Study (30) 
 
Number 
of patients % 
Number of 
patients % 
Fever (F) Present 30 100.0% 30 100.0% 
F+ Rigor (R) Absent 3 10.0%   
 Present 27 90.0% 30 100.0% 
Vomiting (V) Absent 16 53.3% 10 33.3% 
 Present 14 46.7% 20 66.7% 
F+R+V Absent 16 53.3% 10 33.3% 
 Present 14 46.7% 20 66.7% 
Headache Absent 19 63.3% 19 63.3% 
 Present 11 36.7% 11 36.7% 
Abdominal pain Absent 24 80.0% 22 73.3% 
 Present 6 20.0% 8 26.7% 
Loss of appetite Absent 25 83.3% 20 66.7% 
 Present 5 16.7% 10 33.3% 
Anemia Absent 2 6.7% 6 20.0% 
 Present 28 93.3% 24 80.0% 
Splenic enlargement Absent 15 50.0% 16 53.3% 
 Present 15 50.0% 14 46.7% 
Liver enlargement Absent 24 96.0% 28 93.3% 
 Present 1 4.0% 2 6.7% 
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The above table shows various clinical features of the control and the study 
group. 
Out of 60 patients studied, in the control group 46.7% of patients and 
66.7% patients in the study group were complaining of vomiting. The 
difference was statistically not significant. 
  Fever, rigor and vomiting were also complained by 46.7% in control 
group and 66.7% by study group, which was also statistically not significant.  
  Headache was present for 36.7% in both the groups. Abdominal pain 
was present for 20% in control group and 26.7% in study group, which was 
statistically not significant. Loss of appetite was present in 16.7% of control 
group and 33.3% of study group. 
  Anaemia was present in 93.3% of control group and 80% in study 
group. Spleen was enlarged in 50% of control group and 46.7% in study group. 
The difference was statistically not significant. Liver was enlarged in 4% of the 
control and 6.7% in study group. 
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Table 3     PRE TRIAL INVESTIGATIONS 
 Group N Mean Std. Deviation 
Hemoglobin Control 30 9.9536 1.11272 
 Study 30 10.5286 .88270 
Total count Control 30 8126.6667 1191.32882 
 Study 30 7103.3333 1062.36020 
Polymorphs Control 30 51.5667 4.74657 
 Study 30 48.5000 5.02236 
Lymphocytes Control 30 46.1333 4.73966 
 Study 30 47.8000 4.15559 
Monocytes Control 30 2.7000 .95231 
 Study 30 2.6333 .88992 
Eosinophills Control 30 1.6000 1.03724 
 Study 30 2.8667 1.43198 
ESR1/2 Control 30 3.1667 1.17688 
 Study 30 3.0000 .90972 
ESR1 Control 30 6.3333 2.35377 
 Study 30 6.0000 1.81944 
  
 The above table shows the Pre-trial investigations of both the control 
and study group. 
  Before the start of the treatment all the patients under went pre trial 
laboratory investigations like hemoglobin, total count, differential count and 
erythrocytic sedimentation rate. The mean Hemoglobin for control group was 
9.9 and in the study group it was 10.5. There was no statistical significance 
between the two values. Total count in control group was 8126.6 and in study 
group it was 7103.3, here also there was no statistical significance. 
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Polymorphs, in control group were 51.5 and in study group was 48.5. 
Lymphocytes, in control group were 46.1 and in study group was 47.8. 
Monocytes, in control group were 2.7 and in study group 2.6. Eosinophills in 
control group was 1.6 and in study group it was 2.8. There was no statistical 
significance in the differential count in both the groups. ESR in half an hour is 
3.1 in control group and 3 in study group. ESR in one hour is 6.3 in control 
group and 6 in study group. Here also there is no statistical significance in the 
difference between the two groups.             
Table 4    REDUCTION IN TEMPERATURE 
Group 
Control Study 
Time taken for 
normalization of 
temperature 
(in hrs) Number of patients % 
Number 
of patients % 
12 9 30.0 28 93.3 
24 18 85.7 2 100.0 
36 3 100.0   
48 0    
 
 The above table shows reduction in temperature in the control and the 
study group. 
Temperature was reduced to normal in 30% of the patients’ in-group A, 
whereas 93.3% in group B within 12 hrs of drug administration, which is found 
to be statistically significant. 
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  At the end of 24 hrs, temperature was reduced in 85.7% of patients in 
control group whereas 100% reduction in patients in study group (Fig.1). 
  Reduction in temperature is an important clinical sign denoting 
improvement. Within the first 12 hours of drug administration, only 30% of 
patients in the control group had shown reduction in temperature, whereas 
85.7% in the study group had fall in temperature. 
Table 5      REDUCTION IN CHILLS & RIGOR 
Group 
Control Study 
Time taken for 
normalization of 
chills and rigor 
(in hrs) Number of patients % 
Number 
of patients % 
12 9 30.0 28 93.3 
24 16 76.2 2 100.0 
36 5 100.0   
48     
  
The above table shows the reduction in chills and rigor in the control and 
study group. 
Chills and rigor was controlled in 30% of the control group with in 12 hrs 
whereas in the study group 93% had relief, which is statistically highly significant. 
(P=0.001) 
Chills and rigor was controlled in 76% of the patients in control group 
within 24 hrs whereas it was 100% in study group (Fig.2). 
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Table 6   PARASITEMIA CLEARANCE  
Group 
Control Study 
Time taken for 
parasitemia 
clearance (in 
hours, by QBC 
method) 
Number of 
patients % 
Number of 
patients % 
12 3 10.0 18 60.0 
24 16 59.3 11 91.7 
36 8 72.7 1 100.0 
48 3 100.0   
     
 The above table shows clearance of parasitemia by QBC method in the 
control and the study group. 
       The clearance of parasitemia by QBC was 10% with control group within 
12 hours whereas 60% in study group, which is statistically highly significant. 
(P = 0.001) 
  By 24 hrs, it was 60% with control group and 92% with verapamil 
group. It is statistically highly significant. By 36 hrs 73% of the control group 
and 100% of the study group were cleared of parasites (Fig.3). 
 The study has shown that, all the patients in the study group treated 
with chloroquine and verapamil had complete relief of signs and symptoms 
within 36 hours. The duration in temperature, relief from chills and rigor and 
the clearance of parasitemia were significantly earlier than the control group. 
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  All the patients in the control group had relief from symptoms and signs 
by 48 hours but the rate of clearance was found to be slower than the study 
group. 
The difference between the two groups was found to be statistically 
significant indicating that varepamil has facilitated the action of chloroquine. 
Table 7         POST TRIAL INVESTIGATIONS 
 Group N Mean Std. Deviation 
Hemoglobin Control 30 9.7238 1.11354 
 Study 30 10.5151 .87525 
Total count Control 30 9214.4500 1185.35822 
 Study 30 7600.4853 1075.35869 
Polymorphs Control 30 49.5847 4.78569 
 Study 30 50.4153 5.14524 
Lymphocytes Control 30 48.4583 4.79874 
 Study 30 45.4200 4.16584 
Monocytes Control 30 2.7124 .87431 
 Study 30 2.6752 .92452 
Eosinophills Control 30 1.4658 1.25844 
 Study 30 2.2547 1.25848 
ESR1/2 Control 30 3.1547 1.45878 
 Study 30 3.2540 .924582 
ESR1 Control 30 6.4751 2.87574 
 Study 30 6.2541 1.95784 
  
The above table shows the Post-trial investigations done in both control 
and study group.            
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After the treatment all the patients under went post trial laboratory 
investigations like hemoglobin, total count, differential count and erythrocytic 
sedimentation rate. The mean Hemoglobin for control group was 9.7 and in the 
study group it was 10.5. There was no statistical significance between the two 
values. Total count in control group was 9214.4 and in study group it was 
7600.5, here also there was no statistical significance. 
Polymorphs, in control group were 49.5 and in study group was 50.4. 
Lymphocytes, in control group were 48.4 and in study group was 45.4. 
Monocytes, in control group were 2.7 and in study group 2.7. Eosinophills in 
control group was 1.4 and in study group it was 2.2. There was no statistical 
significance in the differential count in both the groups. ESR in half an hour is 
3.1 in control group and 3.2 in study group. ESR in one hour is 6.4 in control 
group and 6.2 in study group. Here also there is no statistical significance in the 
difference between the two groups. 
 The difference between the control group and the study group was not 
statistically significant in both pre trial and post trial laboratory investigations.  
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DISCUSSION 
Among the febrile diseases, though easily diagnosable and treatable, 
malaria still remains a challenging disease of the fatality associated with 
cerebral malaria and the development of resistance by malarial parasites to 
most of the antimalarial drugs. 
 Followed by aminoquinolines, (Chloroquine and its derivatives) several 
other groups of drugs have been introduced (Mefloquine, Halofantrine, 
Artemisinin derivatives etc). Among the available drugs, chloroquine is still the 
effective drug in sensitive malaria. But resistance is common and widespread 
between P.falciparum. High-grade resistance was reported as early in 1978. 
 Resistance among P. vivax was reported in 2000 from Chennai, 
Madhyapradesh and Mumbai 35. Subsequent to the development of resistance to 
chloroquine, several alternative drugs have been used. 
 Mefloquine is effective against both chloroquine sensitive and resistant 
malaria. However like chloroquine, relapses occur in vivax malaria and 
resistance to mefloquine among P. falciparum has been reported from Thailand, 
Cambodia and Myanmar35. Though resistance to mefloquine has not been 
widely reported from India (except in Gujarat), due to its long half-life the 
possibility of selection of resistance strains is high. Resistance to mefloquine 
confers cross-resistance to quinine and halofantrine also.  
 Quinine is an erythrocytic schizonticide effective in most chloroquine 
and multidrug resistant P. falciparum malaria. Though effective in terminating 
the acute attacks of malaria it may not prevent recrudescence. Moreover 
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toxicity of quinine is very high. Cinchonism can occur even after single 
therapeutic dose in sensitive individuals. 
 Pyrimethamine- Sulfonamide combination has supra additive effect and 
highly effective in P. falciparum. But efficacy against P. vivax is low. It is 
contraindicated in infants and those who are allergic to sulfonamide. Though 
resistance to this combination has not been reported in India, resistance is high 
in South East Asia, South America and Southern Africa. 
 The Artemisinin compounds are potent and rapid blood schizonticides. 
Three derivatives are available in India. They are Artemether, Artesunate and 
Arteether. Arteether has been developed in India. They are active against both 
the sensitive and resistant P. falciparum. They produce quicker parasitemia 
clearance than chloroquine. But their duration of action is short and 
recrudescence rate is high when they are used alone. Hence artemisinin 
compounds are combined with drugs like mefloquine to prevent recrudescence. 
 Halofantrine is effective against resistant strains of both P. vivax and 
falciparum. Its schizonticidal activity and its potential to cause cardiac toxicity, 
halofantrine should be used cautiously even in therapeutic dose. 
 Thus, though alternative drugs are available for the treatment of 
chloroquine resistant malaria, resistance to these drugs is also emerging and 
multidrug resistant malaria is prevalent in many parts of the world. 
  Whenever organisms become resistant to the available drugs, two 
modalities of treatment can be followed.  
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1. To select a new drug, if new drug is not available  
2.  To use the existing drug along with another drug which has the property 
of reversing the resistance. 
As chloroquine which has been effective for more than fifty years, has 
recently developed resistance and when drugs which can reverse chloroquine 
resistance have been reported it would be economical to use chloroquine along 
with any one of these resistance reversers rather than finding out a new drug 
which would be very expensive and time consuming. 
Hence it would be appropriate to study the effect of chloroquine 
resistant reversers. The calcium channel blocker verapamil has been reported to 
be an effective resistant reverser by many in-vitro studies 6-16. But its effect in 
sensitive malaria is unknown. By its mechanism of preventing the efflux of 
chloroquine from the parasite by inhibiting the P-glycoprotein 10,15,36,37 (A 
multidrug resistant protein, which increases the efflux of the drug) or inhibition 
of Calcium channel (which is necessary for drug influx), whether it would 
facilitate and prolong the action of chloroquine? Therefore, in order to find out 
its effect in both sensitive and resistant malaria the present study was 
undertaken.  
Sixty patients were included in the study. Both the control (Group A) 
and the test group (Group B) had equal number of thirty patients. All the 
patients were found to belong to lower and lower middle class family. 
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The mean age in control group was 26 years and in study group 23 
years. Even though malaria is common in all the age group, our study group 
had only young adults. Among the 60 patients enrolled in the study, 51 were 
males and 9 were female patients. Even in random allocation the number of 
male patients who entered the study was high in both the groups. The male 
preponderance may be due to the outdoor sleeping habit of male workers.  
46.7% of patients in the control group and 66.7% patients in the study 
group complained of vomiting before treatment. Vomiting is attributed to high 
concentration of parasites and toxemia. After the treatment was started the 
number of patients with vomiting was reduced which may be due to the 
clearance of parasitemia and toxemia. Very few patients complained of 
vomiting even after treatment, which could be due to the drug effect. In the 
study group vomiting was relieved within 12 hours compared to the control 
group. 
Similarly fever and rigor subsided 12 hours earlier in the study group. It 
is due to early clearance of parasitemia. 
Loss of appetite was present in 16.7% of control group and 33.3% of 
study group, which improved within 36 hours of the treatment. 
Reduction in temperature is an important clinical sign denoting 
improvement.  It was reduced to normal in all the patients in-group A within 36 
hours, whereas in-group B within 24 hrs of drug administration (12 hours 
earlier than the control group) which is found to be statistically very 
significant. 
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All the patients in the control group had relief from symptoms and signs 
by 48 hours but the rate of clearance was found to be slower than the study 
group. 
Thus, the study has shown that, all the patients in the study group treated 
with chloroquine and verapamil had complete relief of signs and symptoms 
within 36 hours. The duration of temperature, relief from chills and rigor and 
the clearance of parasitemia were significantly earlier (12 hours) than the 
control group. 
The difference between the two groups was found to be statistically 
significant indicating that verapamil has facilitated the action of chloroquine. 
Though it is reported that in malaria there will be increased leucocyte 
count, increased monocytes 19, and increased ESR, decreased neutrophils, this 
picture was not seen in this study. Anemia was found in 93.3% in control group 
and 80% in study group. The increased incidence of anemia could be due to the 
extensive destruction of RBCs in patients treated with chloroquine alone. 
Verapamil a calcium channel blocker, is known to cause bradycardia, 
hypo tension and constipation due to its inhibitory effect on heart and 
gastrointestinal tract. But none of the patients suffered from hypotension or 
bradycardia. When verapamil is used either as an antihypertansive or 
antiarrhythmic, the duration of therapy is long, whereas in malaria it is used 
only for three days and the maximum dosage administered was only 160 mgm. 
Hence at this dosage verapamil has not produced any side effect and found to 
be very safe. The number of days of stay in the hospital was reduced to two 
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because of the early relief of symptoms. This has reduced the cost on 
hospitalization and helped the patients resume duty at an early date. 
 The beneficial effect of verapamil is as discussed earlier due to its action 
on chloroquine efflux leading to increased concentration of chloroquine in the 
parasite causing early death of the parasites resulting in early relief of signs and 
symptoms.  
  To summarize, the present study has shown that verapamil has a 
definite beneficial effect in malaria when used along with chloroquine. 
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SUMMARY 
 Among the protozoal diseases malaria is the most devastating one and 
cerebral malaria can be fatal if not treated promptly. Several antimalarial drugs 
from the older quinine to the recent artemesinin are available today. Among 
them chloroquine is still the most commonly used and an effective antimalarial 
drug. But resistance to chloroquine developed by the malarial parasites posses a 
great problem in treating malaria. Hence prevention of development of such 
resistance is mandatory to prevent the malarial morbidity.  
Recent studies have shown that drugs such as verapamil, 
chlorpheniramine maleate, desipramine, etc reverse chloroquine resistance. 
Among these, verapamil has been widely reported as an effective resistance 
reverser by in vitro studies. But in vivo study establishing the efficacy of 
verapamil has not been carried out. Hence with an aim of finding out whether 
verapamil will be synergistic when given with chloroquine in all cases of 
malaria, a randomized controlled clinical study was conducted. 
The study has revealed that verapamil is synergistic when given with 
chloroquine by producing early reduction in temperature, early clearance of 
parasitemia and other constitutional symptoms. As the dose administered is 
very small (160 mg total, which can be a single antihypertensive dose) no 
untoward effects occurred in any of the patients. 
Hence this drug can be safely used along with chloroquine in malaria for 
early recovery and to shorten hospitalization as well as reduce the cost of 
therapy.  
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CONCLUSION 
It can be concluded from this study that, 
1. Verapamil is effective in malaria. 
2. Verapamil has a synergistic action when given with chloroquine in 
malaria                
3. It is safe 
4. Hence it can be used along with chloroquine both in sensitive and 
resistant malaria for better efficacy and early recovery. 
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